Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 13;7(2):77-86.
doi: 10.1515/pp-2021-0151. eCollection 2022 Jun 1.

Perception, knowledge and protective practices for surgical staff handling antineoplastic drugs during HIPEC and PIPAC

Hubert Benoist  1 , Clarisse Eveno  2 , Sarah Wilson  3 , Nicolas Vigneron  3 , Jean-Marc Guilloit  4 , Rémy Morello  3 , Nicolas Simon  5 , Pascal Odou  5 , Guillaume Saint-Lorant  1   5
Affiliations

Perception, knowledge and protective practices for surgical staff handling antineoplastic drugs during HIPEC and PIPAC

Hubert Benoist et al. Pleura Peritoneum. .

Abstract

Objectives: Two surgical techniques used for peritoneal metastasis involve a risk of exposure to antineoplastic drugs (ADs): hyperthermic intraperitoneal chemotherapy (HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC). The objective of this study was to assess the differences in perception, training, and knowledge of the risks as well as in the protection practices and occupational exposures of all worker categories.

Methods: This descriptive study, led in two hospitals from two distant French regions, was performed through a face-to-face interview and assessed the perception, knowledge and handling practices of ADs by a questionnaire consisting of 52 questions.

Results: Fifty-one professionals participated in this survey. A total of 29.4% (n=15) professionals were afraid to handle ADs. Very few workers have been trained on handling ADs during initial training dedicated to all caregiver (5.9%; n=3). HIPEC is considered to involve a higher risk of exposure to ADs than PIPAC (81.6% (n=31) vs. 57.9% (n=22), respectively, p=0.022, agreement 65.8%). Protective equipment is considered to be less suitable for HIPEC than for PIPAC (29% (n=11) vs. 10.5% (n=4), respectively, p=0.016, agreement 81.6%). Concerning the potential AD contamination location, the participants identified a significant difference between these two practices. During HIPEC, 15.7% (n=6) of caregivers indicated that they had negative symptoms perceived in their practice vs. 2.6% (n=1) during PIPAC.

Conclusions: This study shows that perception, knowledge and protection practices are different between HIPEC and PIPAC. It also shows a difference between the worker categories. In view of the difficulties in making operating room staff available, the related training programmes must have an adapted format.

Keywords: HIPEC; PIPAC; antineoplastic drugs; occupational risks.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Authors state no conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Klaver YL, Lemmens VE, Nienhuijs SW, Luyer MD, de Hingh IH. Peritoneal carcinomatosis of colorectal origin: incidence, prognosis and treatment options. World J Gastroenterol. 2012;18:5489–94. doi: 10.3748/wjg.v18.i39.5489. - DOI - PMC - PubMed
    1. Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17:1709–19. doi: 10.1016/s1470-2045(16)30500-9. - DOI - PubMed
    1. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998;14:254–61. doi: 10.1002/(sici)1098-2388(199804/05)14:3<254::aid-ssu10>3.0.co;2-u. - DOI - PubMed
    1. Glehen O, Cotte E, Kusamura S, Deraco M, Baratti D, Passot G, et al. Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. J Surg Oncol. 2008;98:242–6. doi: 10.1002/jso.21061. - DOI - PubMed
    1. Solass W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA. Description of a novel approach for intraperitoneal drug delivery and the related device. Zentralbl Chir. 2011;136:28. doi: 10.1055/s-0031-1289059. - DOI - PubMed

LinkOut - more resources